In Brief: GATT patent extensions
GATT patent extensions: The American public will pay an estimated $6 bil. more for 105 brandname drugs due to patent extensions under the GATT-implementing legislation, according to a report released March 17 and sponsored by the National Association of Pharmaceutical Manufacturers and the National Pharmaceutical Association. The two generic drug associations are funding an economic study being conducted by Stephen Schondelmeyer, PhD, at the PRIME Institute to assess the economic impact of GATT legislation on the American public...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth